Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | SCN7A | Q01118 | 2/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17069399 | 1.00 | SCN9A (0.60) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL17061915 | 1.00 | SCN9A (0.60) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL21825501 | 1.00 | SCN9A (0.60) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL18682214 | 1.00 | SCN9A (0.60) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL16771193 | 0.94 | SCN9A (0.67) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL17061699 | 0.94 | SCN9A (0.67) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL16771014 | 0.94 | SCN9A (0.67) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL18682203 | 0.94 | SCN9A (0.67) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL23159312 | 0.90 | SCN9A (0.63) | SCN9AOPRK1KCNH2OPRM1SCN7A | |
| SCHEMBL18675662 | 0.90 | SCN9A (0.63) | SCN9AOPRK1KCNH2OPRM1SCN7A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-09 | — | — | US | disclosed |
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093618-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885OPRK1 1311/4885KCNH2 456/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | SCN9A 1669/4885OPRK1 1787/4885KCNH2 426/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | SCN9A 505/4885OPRK1 1593/4885KCNH2 829/4885 |
| US-20200108054-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, SULT2A1 | SCN9A 1605/4885OPRK1 1311/4885KCNH2 456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.